Skip to content
10-K

Annual Report

Bolt Biotherapeutics, Inc. BOLT

0001193125-26-104121

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 6, 2026 1.92M sh
Shares Diluted FY 2025 · Dec 31, 2025 1.87M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 1.91M sh
Capex FY 2025 · Dec 31, 2025 $72K
Capex FY 2025 · Dec 31, 2024 $41K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$39.85M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$61.29M
Short Term Investments FY 2025 · Dec 31, 2025 $15.8M
Short Term Investments FY 2025 · Dec 31, 2024 $40.12M
Cash And Equivalents FY 2025 · Dec 31, 2025 $11.7M
Cash And Equivalents FY 2025 · Dec 31, 2024 $7.21M
Stockholders Equity FY 2025 · Dec 31, 2025 $26.51M
Stockholders Equity FY 2025 · Dec 31, 2024 $57.2M
Stockholders Equity FY 2025 · Dec 31, 2023 $112.74M
Current Liabilities FY 2025 · Dec 31, 2025 $8.44M
Current Liabilities FY 2025 · Dec 31, 2024 $15.86M
Total Liabilities FY 2025 · Dec 31, 2025 $30.24M
Total Liabilities FY 2025 · Dec 31, 2024 $42.43M
Current Assets FY 2025 · Dec 31, 2025 $30.26M
Current Assets FY 2025 · Dec 31, 2024 $50.81M
Total Assets FY 2025 · Dec 31, 2025 $56.75M
Total Assets FY 2025 · Dec 31, 2024 $99.63M
Eps Diluted FY 2025 · Dec 31, 2025 −$17.85
Eps Diluted restated FY 2025 · Dec 31, 2024 −$33.06
Eps Basic FY 2025 · Dec 31, 2025 −$17.85
Eps Basic restated FY 2025 · Dec 31, 2024 −$33.06
Sga Expense FY 2025 · Dec 31, 2025 $13.8M
Sga Expense FY 2025 · Dec 31, 2024 $18.46M
Rd Expense FY 2025 · Dec 31, 2025 $28.53M
Rd Expense FY 2025 · Dec 31, 2024 $57.47M
Net Income FY 2025 · Dec 31, 2025 −$33.38M
Net Income FY 2025 · Dec 31, 2024 −$63.12M
Operating Income FY 2025 · Dec 31, 2025 −$36.11M
Operating Income FY 2025 · Dec 31, 2024 −$73.05M
Revenue FY 2025 · Dec 31, 2025 $7.7M
Revenue FY 2025 · Dec 31, 2024 $7.69M